Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.

Joaquim Mullol Tanya M Laidlaw Claus BachertLeda P MannentGiorgio Walter CanonicaJoseph K HanJorge F Maspero Cesar Picado Nadia DaizadehBenjamin OrtizYongtao LiMarcella RuddyElizabeth LawsNikhil Amin

Published in: Allergy (2021)

In patients with uncontrolled severe CRSwNP, dupilumab significantly improved objective measures and patient-reported symptoms to a greater extent in the presence of comorbid NSAID-ERD than without. Dupilumab was well tolerated in patients with/without NSAID-ERD.

Keyphrases

atopic dermatitis
placebo controlled
patient reported
double blind
phase iii
early onset
phase ii
clinical trial
open label
study protocol
drug induced
phase ii study
physical activity
depressive symptoms
locally advanced